Skip to main content
27 January 2021 tranScrip is delighted to announce a significant minority investment from Palatine Private Equity Impact Fund, which complements the existing investment of tranScrip’s own Partners. The deal is a landmark for tranScrip, underpinning its growth as a leading specialist service provider. tranScrip’s unique, highly skilled teams combine in-depth pharmaceutical expertise and functional competencies which allow them to lead and deliver successful development, registration and launch of new medicines across multiple therapeutic areas, including oncology, infectious diseases,…
Cambridge, UK – January 26 2021 – The cost of library preparation is one of the biggest obstacles to large next-generation sequencing (NGS) studies, slowing down the pace of insights from infectious disease surveillance, cancer research and beyond. At the Festival of Genomics, SPT Labtech announced an initiative with Thermo Fisher Scientific to co-market solutions that will enable variant detection at a fraction of the cost. Sensitive variant detection can now be achieved at one-tenth of the library prep cost through miniaturization with the SPT Labtech mosquito HV genomics and SPT…
ProductLife Group already has a fairly long success story: born in 1993, focusing on RA since 2006 and after becoming a Group, through acquisitions from 2012 onwards, PLG was reborn once again after LBO by 21Invest. All along, it has kept the ProductLife vision of contributing to improve human health, with its main competences, regulatory affairs, safety & vigilances and quality compliance. In 2020, ProductLife Group has reached a first step of notoriety as PLG, a European leading service provider for top pharmaceutical companies. Those strengths, this recognition, should be kept for the…
Saffron Walden, UK, 21st January 2021 / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to welcome David Cronk, CBiol, MRSB, to the team as its new Chief of Staff. The Company has also promoted long standing team member and previous Head of Chemistry, Dr Ray Boffey, to Executive Director of Medicines Research. Following a successful period of growth and expansion of its research team, both David and Ray bring a wealth of drug discovery experience and will further support Domainex’s ongoing growth plans. David Cronk has over 30 years’ drug discovery…
The cfPure® Cell Free DNA Extraction Kit from AMSBIO is a magnetic bead-based DNA extraction kit designed to isolate circulating cell free DNA (cfDNA) from human plasma or serum samples.Using a quick, simple, and automation friendly protocol the kit allows users to quickly extract high quality cfDNA that is ready for use in downstream applications including next-generation sequencing, Bisulfite Sequencing, PCR, qPCR, ddPCR and other demanding applications. This optimized protocol gives highly reproducible results and higher yields relative to other magnetic bead-based methods.…
Research Triangle Park, NC, USA and Cambridge, UK, 20 January 2021 – Inivata, a leader in liquid biopsy, today announces that the first patients have been tested using InVisionFirst®-Lung as part of the Phase II ALKALINE trial sponsored by the European Organisation for Research and Treatment of Cancer (EORTC). As part of the study Inivata’s InVisionFirst-Lung liquid biopsy will be used to test and monitor ALK positive non-small cell lung cancer (NSCLC) patients initiating treatment with lorlatinib, Pfizer Inc.’s third generation ALK inhibitor therapy. The aim of this academic trial, announced…
Cambridge and London, UK, 18 January 2021: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement. The collaboration is focused on the discovery of novel selective small molecular modulators of a specific two-pore domain potassium ion channel target, identified as likely to be involved in neurological pathogenesis, and has now…
Cambridge, United Kingdom – 14 January 2021 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces the launch of a Patient Advocacy and Engagement Advisory Board. Working with the Congenica Board of Directors and wider senior leadership team, this group of leading advocacy professionals and experts in rare diseases, genetics and precision medicine will ensure that the patient perspective remains at the heart of Congenica’s strategy. Alongside this, the new board will serve to inform patients and…
Taiho Pharmaceutical Co, Ltd., (hereinafter Taiho) announces that it and Astex Pharmaceuticals (UK), (hereinafter Astex), both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada (hereinafter MSD) through a subsidiary.  An option for MSD to acquire the exclusive license to the Astex-Taiho SHP2 program was included as part of the strategic oncology collaboration between MSD, Astex and Taiho, announced in January 2020…
Cambridge, UK, 13 January 2021: Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, was honored with a Employees’ Choice Award recognizing the Best Places to Work in 2021 by Glassdoor, the worldwide leader on insights about jobs and companies. Nick Skinner, SVP Human Resources at Abcam commented: “I am delighted by the positive feedback received from our employees, especially over the past year. Delivering our ambitious strategy depends on our engaged global team and I am proud of what we’ve achieved together. We continuously strive to better support the…